In this episode, we review the 2026 Consensus Statement on Lipid Management in Adults with Type 2 Diabetes. Topics include ASCVD risk assessment, LDL-C treatment targets, statin therapy, coronary artery calcium scoring, nonstatin lipid lowering therapies, triglyceride management, and key differences between ACC/AHA and AACE recommendations. We also discuss practical treatment strategies and board relevant pearls for cardiovascular risk reduction.

In this episode, we review the 2026 Consensus Statement on Diabetes Classification in Adults. Topics include diagnostic criteria for diabetes, distinguishing type 2 diabetes from autoimmune, pancreatogenic, monogenic, endocrinopathy associated, and medication induced diabetes, and the role of phenotype, autoantibody testing, and C-peptide measurement in establishing the correct diagnosis. We also discuss key clinical features that should prompt reconsideration of a diabetes diagnosis and how accurate classification can guide appropriate treatment selection and improve patient outcomes.

In this episode, we review the latest 2026 Consensus Statement recommendations for the evaluation and management of prediabetes. Topics include updated diagnostic criteria, the recognition of prediabetes as a cardiometabolic disease state, lifestyle interventions as the foundation of therapy, and strategies to prevent progression to type 2 diabetes. We also discuss comprehensive cardiovascular risk reduction, weight loss goals, the role of anti obesity medications and bariatric surgery, evaluation of lean prediabetes, pharmacologic options for diabetes risk reduction, and key clinical pearls for optimizing long term patient outcomes. Learn how early identification and comprehensive management can reduce future diabetes and cardiovascular disease burden.

This episode reviews major updates in ASCVD risk stratification and lipid management from the AHA/ACC lipid guideline. Topics include cumulative apolipoprotein B exposure assessment, updated low density lipoprotein cholesterol estimation methods, expanded clinical use of apolipoprotein B and lipoprotein(a), integration of cardiovascular kidney metabolic syndrome into preventive cardiology, revised triglyceride referral thresholds, PREVENT ASCVD risk equations, high sensitivity C-reactive protein guided statin therapy considerations, and the evolving role of coronary artery calcium scoring in refining lipid lowering intensity and individualized cardiovascular risk reduction.

This episode reviews major updates in lipid management for ASCVD risk reduction. Topics include revised LDL-C estimation equations, expanded clinical application of apolipoprotein B for residual atherogenic risk assessment, universal lipoprotein(a) screening, and cardiovascular kidney metabolic syndrome as a risk enhancing condition. The episode also discusses triglyceride referral thresholds, reproductive and inflammatory ASCVD risk enhancers, high sensitivity C-reactive protein guided statin considerations, and the role of coronary artery calcium scoring in refining lipid lowering therapy and cardiovascular risk stratification.

This episode applies risk based lipoprotein targets across specific clinical scenarios for atherosclerotic cardiovascular disease risk reduction. It highlights how severe hypercholesterolemia, diabetes, subclinical atherosclerosis, hypertriglyceridemia, and clinical ASCVD are stratified using the same three tier framework of 100/130/90, 70/100/70, and 55/85/55. It emphasizes the role of coronary artery calcium in refining risk, the use of apoB to assess atherogenic particle burden, and the distinction between patients with and without established ASCVD. It also reinforces that diabetes without ASCVD does not meet criteria for the most intensive targets and that consistent numeric thresholds guide management across varying clinical presentations.

This episode reviews risk based lipoprotein targets for atherosclerotic cardiovascular disease risk reduction. It highlights LDL-C, non-HDL-C, and apolipoprotein B as key parameters, with goals stratified by overall ASCVD risk category. It emphasizes the three tier framework of 100/130/90 for low risk, 70/100/70 for intermediate risk, and 55/85/55 for high or very high risk patients. It also covers primary versus secondary prevention targets, the role of apoB in refining atherogenic burden, especially in hypertriglyceridemia, and the importance of assigning risk first before applying lipid goals in clinical practice.

This episode reviews the clinical application of lipoprotein(a) and apolipoprotein B in cardiovascular risk assessment based on AHA ACC guidance. It emphasizes the genetic determination and stability of lipoprotein(a), supporting its role as a one time measurement for risk stratification, along with the importance of cascade screening in identifying inherited risk. The discussion outlines how lipoprotein(a) levels correlate with graded increases in cardiovascular risk and contribute to atherosclerosis, thrombosis, and calcific aortic valve disease. It also highlights apolipoprotein B as a direct measure of atherogenic particle burden, providing additional risk refinement beyond traditional cholesterol metrics, particularly in patients with metabolic disease or discordant lipid profiles. Key takeaways include appropriate use of advanced lipid markers, integration with PREVENT risk estimation, recommended monitoring strategies during lipid lowering therapy, and evidence based thresholds for treatment intensification to reduce long term cardiovascular risk..

This episode reviews standard lipid measurements for cardiovascular risk assessment based on AHA/ACC guidelines. It highlights the use of non-fasting lipid testing for most patients, key indications for fasting testing, and modern LDL cholesterol calculation methods. It also covers the role of non-HDL cholesterol and the limited utility of advanced lipoprotein testing in clinical practice.

This episode reviews the importance of dyslipidemia screening across both pediatric and adult populations based on AHA ACC guidelines. It highlights the epidemiology and clinical impact of dyslipidemia, emphasizing the role of cumulative low density lipoprotein cholesterol exposure in determining lifetime cardiovascular risk. The discussion covers universal screening strategies, limitations of family history based screening, and practical approaches to identifying high risk individuals, including those with familial hypercholesterolemia. Key takeaways include recommended screening intervals, age based strategies, appropriate use of lipid testing, and the importance of early detection and intervention to reduce long term cardiovascular morbidity and mortality.